NEWS
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, when combined with immunotherapy, has shown promising results in controlling disease and tumor response in head and neck cancer patients. Detailed insights from the 2024 ASCO Annual Meeting will be reviewed, highlighting NBTXR3's mechanisms, patient treatment responses, and its potential role in addressing unmet medical needs in recurrent or metastatic head and neck cancer. Registration for the event is available online, and it will be replayed and archived on the company's website.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1103Followers
69Following
7653Visitors
Follow